Ozempic vs Mounjaro for PMOS: Which Works Better?

Ozempic vs Mounjaro for PMOS is now one of the most common questions we get, and most articles answer it by comparing two numbers from two different trials. That comparison is close to meaningless, because the trials enrolled different people for different lengths of time.

This page does it properly. It uses the two 2025 Cochrane reviews, which are the highest quality evidence that exists for either drug, and it reports the certainty rating alongside every number. Certainty is the part everyone leaves out, and in this comparison it changes the answer.

PMOS is Polyendocrine Metabolic Ovarian Syndrome, the clinical name adopted for PCOS in May 2026. Semaglutide is sold as Ozempic and Wegovy. Tirzepatide is sold as Mounjaro and Zepbound.

Ozempic vs Mounjaro: the numbers side by side

Both drugs were assessed by Cochrane in October 2025 against placebo, not against each other. The comparison below is therefore indirect, and the sample sizes and certainty ratings matter as much as the effect sizes.

Which one causes more weight loss?

Tirzepatide, by roughly five percentage points of body weight. The 2025 Cochrane review of tirzepatide pooled eight studies covering 6,317 participants and found a mean reduction of 16.03% of body weight against placebo at 12 to 18 months (95% CI -18.91 to -13.14).

The semaglutide review pooled 15 studies covering 8,651 participants and found 10.73% (95% CI -12.24 to -9.21) over 6 to 17 months.

For a woman weighing 90 kg, that difference is roughly 14.4 kg against 9.7 kg. It is a real gap and it is the reason tirzepatide has taken over the conversation.

An indirect treatment comparison published in Diabetes, Obesity and Metabolism in 2025 reached the same conclusion. Tirzepatide at 10 mg and 15 mg produced significantly greater reductions in weight, BMI and HbA1c than semaglutide 2.4 mg, and tirzepatide 15 mg also improved waist circumference, fasting glucose and triglycerides. Safety profiles were broadly similar.

Which one has the better evidence?

Semaglutide, and this is the part almost every comparison omits. Cochrane rates the semaglutide weight-loss estimate as high certainty and the tirzepatide estimate as moderate certainty.

High certainty means further research is very unlikely to change the estimate. Moderate certainty means further research may well change it. So tirzepatide's larger number is also the less settled number.

There is a second problem that applies to both. Cochrane noted that all of the included tirzepatide studies and most of the semaglutide studies were funded by the manufacturer of the drug being tested. The reviewers flagged this explicitly as a conflict-of-interest concern and called for independent studies.

Which is better for PMOS specifically?

Nobody knows, because the head-to-head trial in PMOS does not exist. What exists is one PMOS-specific tirzepatide trial and a longer history of small semaglutide studies.

The tirzepatide trial was published in Diabetes, Obesity and Metabolism in August 2026. It randomised 60 overweight or obese Chinese women with PMOS to metformin 1000 mg twice daily, or the same metformin plus tirzepatide 5 mg weekly, for 16 weeks.

• Weight: -10.4 kg on the combination against -1.7 kg on metformin alone
• BMI: -4.12 against -0.68 kg/m2
• Visceral fat: -34.13 cm2 against -4.67 cm2
• Menstrual cycle recovery was higher on the combination (P = 0.013)

The visceral fat result is the one that matters most for PMOS. Visceral fat drives insulin resistance, and insulin resistance drives the androgen problem. A seven-fold difference there is more relevant to your symptoms than the scale number.

The limits are large. Sixty women, one centre, open-label, 16 weeks, and a low 5 mg dose. Everyone was switched back to metformin alone afterwards.

What about side effects?

Similar in kind, slightly worse in degree with tirzepatide. Both drugs cause mostly mild to moderate gastrointestinal effects: nausea, constipation, reflux and early fullness.

The number worth comparing is how many people quit because of side effects. Against placebo, that risk ratio was 1.84 for semaglutide and 2.06 for tirzepatide. Both reviews rated serious adverse event evidence as very uncertain, which means neither review can tell you much about rare harms.

Most of the gastrointestinal misery is manageable through food rather than through dose changes. We cover the specific swaps in GLP-1 side effects with PCOS and what to eat for relief.

Do either of them protect your heart?

Semaglutide has the better signal, and it is still not conclusive. Cochrane found a risk ratio of 0.63 for major adverse cardiac events with semaglutide across 9 studies and 7,647 participants, and 0.69 for mortality across 14 studies. Both were rated low certainty.

Tirzepatide showed a risk ratio of 0.75 for major cardiac events, which Cochrane described as little to no difference, at moderate certainty.

This matters more for PMOS than it does for the general population. PMOS carries elevated cardiovascular and metabolic risk over a lifetime, so a drug with a cardiovascular signal has value beyond the scale.

Do both cause muscle loss?

Yes, and the number is larger than most people are told. A 2026 systematic review and meta-analysis in Diabetes/Metabolism Research and Reviews pooled 36 randomised trials and found that GLP-1 receptor agonists reduced lean body mass by 1.51 kg on average (95% CI -2.00 to -1.01).

The proportion is the striking part. Across the pooled trials, lean mass accounted for 28% of total weight lost (95% CI 22% to 34%). Results were not modified by sex.

So for every 10 kg lost, roughly 2.8 kg is lean tissue rather than fat. For a woman with PMOS, losing muscle is directly counterproductive, because skeletal muscle is where most glucose gets disposed of. Less muscle means worse insulin sensitivity, which is the thing you are trying to fix.

What happens if you stop either one?

You regain, and the two drugs behave similarly. In the STEP 1 trial extension, participants regained two-thirds of their lost weight in the year after stopping semaglutide. In the SURMOUNT-4 trial, people switched from tirzepatide to placebo gained 14.0% of body weight back over 52 weeks while those who continued lost a further 5.5%.

Neither drug is a course of treatment that ends. Both behave like blood pressure medication: the effect lasts while you take it. We go through the numbers and the practical planning in what happens when you stop a GLP-1 with PMOS.

How do you choose between them?

The honest framework is that this is mostly not your decision alone. Access, insurance, supply and your doctor's judgement will narrow it before preference does. Within what is available to you, the evidence supports a simple split.

What should you eat on either drug?

The same thing, because the eating problem is identical on both. Both drugs slow gastric emptying and cut appetite hard. That produces two failures that no dose adjustment fixes.

Failure one: not enough protein. With 28% of weight loss coming from lean tissue, protein stops being optional. Aim for 1.2 to 1.6 g per kg of body weight, front-loaded into the first meal while appetite is highest.

Failure two: not enough food overall. Very low intake accelerates lean mass loss and makes the nausea worse, not better.

Meals that work on a suppressed appetite are protein-dense, small in volume and low in fat, since fat slows stomach emptying further. From our recipe database:

• Broiled Salmon with Asparagus, 42 g protein in 453 calories. Among the best protein-per-bite options when you can only manage a small plate.
• Red Lentil Sweet Potato Curry, 19 g protein in 358 calories. Soft textures are easier on the days nausea is bad.
• Spicy Chickpea Chole, 11 g protein in 244 calories, useful for building a light second meal.

Which drug fits your situation?

Score each statement that is true, then read the interpretation.

• My main goal is the largest possible reduction in visceral fat. (Tirzepatide point)
• I have a family history of heart disease. (Semaglutide point)
• I have struggled with nausea on other medications. (Semaglutide point)
• I want the option with the most settled long-term data. (Semaglutide point)
• I have tried semaglutide and plateaued. (Tirzepatide point)
• Cost or insurance restricts me to one option. (The decision is already made)

Mostly semaglutide points: start the conversation with Ozempic or Wegovy. The evidence is more settled and the cardiovascular signal is better.

Mostly tirzepatide points: Mounjaro or Zepbound has the larger effect, and the August 2026 PMOS trial is the only PMOS-specific randomised data available.

Split or unsure: the difference between these two drugs is smaller than the difference between taking either one with a protein plan and taking it without one. Sort the food first.

Myths about Ozempic vs Mounjaro for PMOS

Myth: Mounjaro is simply the better drug.
Reality: It produces more weight loss at moderate certainty. Semaglutide produces less at high certainty and carries the better cardiovascular signal. Those are different kinds of better. Share this

Myth: There is a trial showing which one is better for PCOS.
Reality: There is not. One PMOS-specific tirzepatide trial exists, with 60 participants over 16 weeks. No head-to-head comparison in PMOS has ever been run. Share this

Myth: The weight you lose is fat.
Reality: Across 36 randomised trials, lean mass accounted for 28% of the weight lost on GLP-1 medications. For PMOS that is counterproductive, because muscle is where glucose gets disposed of. Share this

Myth: You can stop once you reach your goal weight.
Reality: In SURMOUNT-4, people switched to placebo regained 14.0% of body weight over 52 weeks. In the STEP 1 extension, participants regained two-thirds of their loss within a year. Share this

Myth: The trials are neutral science.
Reality: Cochrane reported that all included tirzepatide trials and most semaglutide trials were funded by the manufacturer, and flagged this as a conflict-of-interest concern. Share this

Myth: Diet does not matter once you are on a GLP-1.
Reality: Diet determines how much of the loss is muscle rather than fat. The drug controls how much you eat. It does not control what you eat. Share this

Frequently asked questions

Is Mounjaro or Ozempic better for PMOS?
Neither has been shown better for PMOS, because no head-to-head trial in PMOS exists. In the general obesity evidence, tirzepatide produces more weight loss, with Cochrane finding 16.03% against placebo compared with 10.73% for semaglutide. However, the semaglutide estimate is rated high certainty and the tirzepatide estimate only moderate certainty, so the larger number is also the less settled one. Semaglutide additionally shows a better signal on major cardiac events. For PMOS specifically, the only randomised data is a 60-person, 16-week trial of tirzepatide added to metformin. Access, insurance and your doctor's judgement will usually settle this before evidence does. Share this

How much more weight will I lose on tirzepatide than semaglutide?
Based on the 2025 Cochrane reviews, roughly five percentage points of body weight. Tirzepatide averaged 16.03% reduction against placebo across 8 studies and 6,317 participants. Semaglutide averaged 10.73% across 15 studies and 8,651 participants. For someone weighing 90 kg, that is approximately 14.4 kg against 9.7 kg. These come from separate trials with different populations and durations, so treat the gap as an estimate rather than a precise figure. An indirect treatment comparison in 2025 reached the same directional conclusion, with tirzepatide 10 mg and 15 mg outperforming semaglutide 2.4 mg on weight, BMI and HbA1c.

Which has worse side effects?
Tirzepatide, marginally. Both cause predominantly mild to moderate gastrointestinal effects including nausea, constipation, reflux and early fullness. The most useful comparison is the rate of quitting because of side effects. Against placebo, that risk ratio was 2.06 for tirzepatide and 1.84 for semaglutide. Both Cochrane reviews rated the evidence on serious adverse events as very uncertain, so neither can tell you much about rare harms. Most gastrointestinal symptoms respond better to changes in meal size, fat content and eating pace than to changing drugs.

Do GLP-1 medications help PMOS symptoms or just weight?
Both, though the symptom evidence is thinner. The August 2026 tirzepatide trial in women with PMOS found higher menstrual cycle recovery on the combination arm than on metformin alone. A 2026 Lancet Diabetes and Endocrinology review concluded that GLP-1 based therapies show benefits across obesity-related conditions including PMOS, and that some benefits are independent of weight loss itself. The mechanism is plausible: reducing visceral fat improves insulin sensitivity, and lower insulin reduces ovarian androgen production. The August 2026 trial found a 34.13 cm2 reduction in visceral fat against 4.67 cm2 with metformin alone.

Will I lose muscle on either drug?
Yes, on both. A 2026 meta-analysis of 36 randomised trials found GLP-1 receptor agonists reduced lean body mass by 1.51 kg on average, and that lean mass made up 28% of total weight lost, with a confidence interval of 22% to 34%. Results were not modified by sex. This matters more with PMOS than in the general population, because skeletal muscle is the primary site of glucose disposal. Losing muscle worsens insulin sensitivity, which is the underlying problem. The countermeasures are adequate protein, roughly 1.2 to 1.6 g per kg of body weight, and resistance training two to three times a week. Share this

What happens if I stop taking it?
You regain most of the weight, on either drug. The STEP 1 trial extension followed participants for a year after semaglutide was withdrawn. Mean weight loss was 17.3% at week 68, and participants regained 11.6 percentage points by week 120, leaving a net 5.6%. The authors described this as regaining two-thirds of prior weight loss, and noted that cardiometabolic improvements reverted toward baseline. SURMOUNT-4 found the same pattern with tirzepatide: those switched to placebo gained 14.0% of body weight over 52 weeks, while those continuing lost a further 5.5%. Only 16.6% of the placebo group kept at least 80% of their loss, against 89.5% of those who continued.

Can I switch from Ozempic to Mounjaro?
This is a prescribing decision, and plateau on semaglutide is a recognised reason clinicians consider it. There is no trial evidence on switching in women with PMOS. What the evidence does say is that tirzepatide produces greater weight reduction on average, so a switch has a reasonable rationale if semaglutide has stalled at a maximum tolerated dose. Expect the gastrointestinal side effects to reset, since tolerance built to one drug does not transfer. Do not bridge a gap between prescriptions with compounded or unregulated product.

Do these drugs work if I have PMOS but a normal BMI?
The evidence does not answer this, because essentially all of the trial data comes from participants with obesity or overweight plus a weight-related complication. The August 2026 PMOS trial specifically enrolled overweight or obese women. Lean PMOS is a real phenotype with insulin resistance that is not explained by body weight, and it has been badly served by research. If you have PMOS at a normal BMI, this is a question for an endocrinologist rather than a decision to make from published trials, since the risk and benefit balance shifts when there is less excess fat to lose.

Is compounded semaglutide or tirzepatide the same thing?
No. Every number on this page comes from trials of the manufactured product at defined doses. Compounded versions are not the studied product, dosing accuracy varies, and the safety data does not transfer. This is a straightforward safety point rather than a brand preference. If cost is the barrier, that is worth raising directly with your prescriber, because dose, formulation and access programmes are all negotiable in ways the underlying prescription is not.

What to do next

1. Work out what is actually available to you. Insurance and supply narrow this decision more than evidence does. Find out what you can access before optimising between two options.
2. Set your protein target now. Multiply your weight in kg by 1.2 and by 1.6. That range is your daily protein target, and it matters more than the drug choice.
3. Book resistance training into the week. Two to three sessions. This is the countermeasure to the 28% lean mass finding.
4. Take three questions to your appointment. Which drug your plan covers, what the plan is if you plateau, and what happens when you want to stop.
5. Sort the food before the first injection. Build a free PMOS meal plan around your protein target, so week one is not improvised on no appetite.

How this article was made

Every figure here comes from the published abstract of a named study, read in full before writing. The two primary sources are the Cochrane reviews of tirzepatide (CD016018) and semaglutide (CD015092), both published 30 October 2025, chosen because systematic reviews with formal certainty grading are the highest quality evidence available for either drug.

Certainty ratings are reported alongside every effect size, because an effect size without its certainty rating is half a result. Where the two drugs have not been compared directly, that is stated rather than papered over with numbers from unrelated trials. Cochrane's own conflict-of-interest finding about manufacturer funding is reported because it applies to nearly the entire evidence base.

Where to go from here

Choosing between Ozempic and Mounjaro for PMOS matters less than what you do in the kitchen while you take either one. The drug decides how much you eat. Everything else is still yours.

• Build your free PMOS meal plan around your protein target and the foods you can actually face.
• Read the full pros and cons in our honest guide to GLP-1s for PMOS.
• Compare against the older option in Ozempic vs metformin for PCOS.
• Get the meal mechanics right in what to eat on a GLP-1 with PCOS.
• Follow new research as it lands on our Telegram channel.

If you have taken both drugs, tell us what actually differed for you. Those comparisons are the ones no trial has run.